|
KMID : 1009020210190010160
|
|
Clinical Psychopharmacology and Neuroscience
2021 Volume.19 No. 1 p.160 ~ p.165
|
|
|
A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
|
|
Lee Kyung-Ho
Bahk Won-Myong
Lee Soo-Jung
Serretti Alessandro
Pae Chi-Un
|
|
|
Abstract
|
|
|
Objective: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice.
Methods: Nine patients were prescribed Neuropharmagenⓡ for selection of antidepressants for individual patient and their clinical outcomes were followed.
Results: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients.
Conclusion: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.
|
|
|
KEYWORD
|
|
|
Treatment, Depressive disorder, Antidepressive agent, Treatment-resistance, Clinical outcome
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|